Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.63 |
| ▸ | KRAS | P01116 | 5/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323762 | 0.93 | ABCG2 (0.64) | ABCG2KRASCA1CA2ABCB1 | |
| SCHEMBL25296474 | 0.85 | ABCG2 (0.81) | ABCG2KRASCA1CA2ABCB1 | |
| SCHEMBL28263079 | 0.85 | ABCG2 (0.81) | ABCG2KRASCA1CA2ABCB1 | |
| SCHEMBL6456490 | 0.82 | TUBB4A (0.59) | CYP1A2ALDH1A1 | |
| SCHEMBL31266997 | 0.81 | TUBB1 (0.60) | ABCB1 | |
| SCHEMBL14800858 | 0.78 | ABCG2 (0.84) | ABCG2KRASCA1CA2ABCB1 | |
| SCHEMBL14820484 | 0.78 | ABCG2 (0.84) | ABCG2KRASCA1CA2ABCB1 | |
| SCHEMBL6009747 | 0.78 | ABCG2 (0.80) | ABCG2KRASCA1CA2ABCB1 | |
| SCHEMBL29960098 | 0.78 | ABCG2 (0.80) | ABCG2KRASCA1CA2ABCB1 | |
| SCHEMBL5614582 | 0.78 | TUBB1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453783-B1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA SA (FR) | 2006-10-04 | — | — | EP | disclosed |
| US-6887904-B2 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-05-03 | — | — | US | disclosed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | ABL1, MCL1, AHR | ABCG2 270/4885KRAS 8/4885CA1 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.